Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Hepatology

• Publication date

  2007-12-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hep.22061PMID 18069698
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

  2007cited by this paper
• Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

  2006cited by this paper
• Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

  2006cited by this paper
• Re‐treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon‐alpha‐2a (40 kDa) and ribavirin

  2006cited by this paper
• Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.

  2006cited by this paper
• Short-term treatment duration for HCV-2 and HCV-3 infected patients.

  2006cited by this paper
• Optimizing outcomes in hepatitis C: is treatment beyond 48 weeks ever justified?

  2006cited by this paper
• Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C

  2005cited by this paper
• Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

  2005cited by this paper
• Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women

  2005cited by this paper
• Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

  2005cited by this paper
• External Validation of Biochemical Indices for Noninvasive Evaluation of Liver Fibrosis in HCV Chronic Hepatitis

  2005cited by this paper
• Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

  2005cited by this paper
• A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus.

  2004cited by this paper
• Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients.

  2004cited by this paper
• Diagnosis, management, and treatment of hepatitis C

  2004cited by this paper
• Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial.

  2004cited by this paper
• Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

  2004cited by this paper
• Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study

  2004cited by this paper
• Extending combination therapy with peginterferon alfa‐2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases

  2003cited by this paper
• Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C

  2003cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Classification of chronic hepatitis: Diagnosis, grading and staging

  1994cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Mesenchymal Cell-Derived Exosomes as Novel Useful Candidates for Drug Delivery

  2020cites this paper
• The Clinical Utility of Vitamin D Levels in Management of Treatment Naive Chronic HCV Infection

  2019cites this paper
• Shortened peginterferon and ribavirin treatment for chronic hepatitis c

  2019influential citation
• A Predictive Scoring Model for Relapse in Chronic HCV Patients with Rapid Virologic Response to PEG Interferon / Ribavirin Treatment

  2019cites this paper
• [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection].

  2018cites this paper
• Effect of Extracellular Vesicles Derived From Mesenchymal Stem Cells on K-562 Leukemia Cell Line

  2018cites this paper
• Background: On-treatment HCV kinetics play an invaluable role in evaluating the efficacy of interferon-based thera-

  2017cites this paper
• ASSOCIATION OF OBESITY WITH RAPID VIROLOGICAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C

  2017cites this paper
• Interferon and ribavirin for chronic hepatitis C: should it be administered in the new treatment era?

  2017cites this paper
• Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy.

  2016cites this paper
• The Role of Pathological Staging in Selection of Appropriate Treatment Option for Autoimmune Hepatitis: Findings of a Prospective Observational Study

  2016cites this paper
• Diagnostics in hepatitis C: The end of response-guided therapy?

  2016cites this paper
• KASL clinical practice guidelines: management of hepatitis C

  2016cites this paper
• An open , non-controlled clinical study to assess the efficacy and safety of the recombinant human alpha 2 b pegylated interferon PEG-Heberon ® plus ribavirin for the treatment of chronic hepatitis C virus infection in Cuban patients

  2016cites this paper
• Comparison of the Abbott RealTime HCV and Roche COBAS Ampliprep/COBAS TaqMan HCV Assays for the Monitoring of Sofosbuvir-Based Therapy

  2016cites this paper
• Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C

  2016cites this paper
• Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial

  2015cites this paper
• Cost-effectiveness of screening for hepatitis C in Canada

  2015cites this paper
• PharmGKB summary: peginterferon-&agr; pathway

  2015cites this paper
• Impact of interleukin‐28B polymorphism on HCV‐1 infected patients treated with response‐guided therapy

  2015cites this paper
• Mexican consensus on the diagnosis and management of hepatitis C infection.

  2015cites this paper
• Biomarkers in HCV Infection.

  2015cites this paper
• End-of-Treatment-Response in patients treated for hepatitis C virus with standard interferon and ribavirin based on viral load.

  2015cites this paper
• Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.

  2015cites this paper
• Estudio clínico abierto, no controlado para la evaluación de la seguridad y eficacia del interferón alfa 2b pegilado PEG-Heberon® más ribavirina para el tratamiento de la infección crónica por el virus de la hepatitis C en pacientes cubanos

  2015cites this paper
• Use of antiviral therapy in patients with chronic hepatitis C

  2015cites this paper
• A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial.

  2014cites this paper
• Prevalence of vitamin D deficiency and insufficiency in Bulgarian patients with chronic Hepatitis C viral infection

  2014cites this paper
• Hepatitis C virus relapse was suppressed by long‐term self‐injection of low‐dose interferon in patients with chronic hepatitis C after pegylated interferon plus ribavirin treatment

  2014cites this paper
• Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated‐interferon and ribavirin

  2014cites this paper
• In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions

  2014cites this paper
• Association between baseline parameters and end of treatment response to combination of conventional interferon & ribavirin in patients with chronic Hepatitis C

  2014cites this paper
• Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection.

  2014cites this paper
• Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor

  2014cites this paper
• An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.

  2014cites this paper
• Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa

  2014cites this paper
• Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.

  2014cites this paper
• Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection.

  2014cites this paper
• Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1

  2014cites this paper
• Polymorphisms in the IFNL3/IL28B gene and hepatitis C: from adults to children.

  2014cites this paper
• Study of outcome of naïve and previous nonresponder hepatitis C virus Egyptian children treated with combined therapy of pegylated interferon plus ribavirin

  2014cites this paper
• The future of dual therapy for hepatitis C virus

  2014cites this paper
• Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice

  2014cites this paper
• Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy

  2014cites this paper
• Current issues in comparative effectiveness research for hepatitis C

  2014cites this paper
• Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C.

  2014cites this paper
• Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial

  2014cites this paper
• KASL clinical practice guidelines: Management of Hepatitis C

  2014cites this paper
• Indices of initial hepatitis C virus RNA reduction rate to predict efficacy of interferon‐beta followed by peginterferon plus ribavirin for genotype 1b high viral load

  2014cites this paper
• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2014cites this paper
• Response‐guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects

  2014cites this paper
• Individualisation of drug treatments for patients with long-term conditions: a review of concepts

  2014cites this paper
• Baseline High Viral Load and Unfavorable Patterns of Alanine Aminotransferase Change Predict Virological Relapse in Patients With Chronic Hepatitis C Genotype 1 or 2 Obtaining Rapid Virological Response During Antiviral Therapy

  2013cites this paper
• Chikungunya virus: an update on antiviral development and challenges

  2013cites this paper
• IL-4 , IL-12 and TNF-α Cytokines Productivity in Chronic Hepatitis C Infected Patients Treated with Bee Stings

  2013cites this paper
• Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.

  2013cites this paper
• Association between an IL‐28B genetic polymorphism and the efficacy of the response‐guided pegylated interferon therapy in children with chronic hepatic C infection

  2013cites this paper
• A multicenter survey of re‐treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan

  2013cites this paper
• Clinical Practice Guidelines : Management of hepatitis C virus infection European Association for the Study of the Liver ⇑

  2013cites this paper
• Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection.

  2013cites this paper
• Baseline viral load - a predictor of treatment response in advanced hepatitis C

  2013cites this paper
• Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C.

  2013cites this paper
• The Impact of Imprecision in HCV Viral Load Test Results on Clinicians’ Therapeutic Management Decisions and on the Economic Value of the Test

  2013cites this paper
• EASL Clinical Practice Guidelines: Management of hepatitis C virus infection European Association for the Study of the Liver ⇑

  2013cites this paper
• Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin

  2013cites this paper
• [Boceprevir: new possibilities for antiviral treatment of chronic hepatitis C].

  2013cites this paper
• Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons &agr;-2a and &agr;-2b, plus ribavirin

  2013cites this paper
• Futility of antiviral treatments for hepatitis C: an evolving concept entering the direct antiviral agents era.

  2013cites this paper
• Development of boceprevir: a first‐in‐class direct antiviral treatment for chronic hepatitis C infection

  2013cites this paper
• Sustained and rapid virological responses in hepatitis C clinical trials

  2013cites this paper
• Value-based assessment of pharmacodiagnostic testing from early stage development to real-world use.

  2013cites this paper
• Various Predictors of Sustained Virologic Response in Different Age Groups of Patients With Genotype-1 Chronic Hepatitis C

  2013cites this paper
• Patients younger than forty years old with hepatitis C virus genotype-1 chronic infection had treatment responses similar to genotype-2 infection and not related to interleukin-28B polymorphism.

  2013cites this paper
• Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b

  2013cites this paper
• Effect of Prolongation of Combined Treatment in HCV-4 Infection

  2013cites this paper
• SHORTENED PEGINTERFERON AND RIBAVIRIN TREATMENT FOR CHRONIC HEPATITIS C

  2012influential citation
• Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin

  2012cites this paper
• Recent trends in the treatment of chronic hepatitis C

  2012cites this paper
• Peginterferon alfa‐2b plus weight‐based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response

  2012cites this paper
• Interleukin 28B Genetic Polymorphisms Play a Minor Role in Identifying Optimal Treatment Duration in HCV Genotype 1 Slow Responders to Pegylated Interferon plus Ribavirin

  2012influential citation
• Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin.

  2012influential citation
• Individualized Therapy for Chronic Hepatitis C

  2012cites this paper
• Yttrium 90 therapy for hepatocellular carcinoma: Is it any better than conventional external beam radiotherapy?

  2012cites this paper
• Chronic hepatitis C virus

  2012cites this paper
• Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa‐2a/ribavirin

  2012cites this paper
• Rapid virological response: Is it four or eight weeks?

  2012cites this paper
• Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy.

  2012cites this paper
• Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa‐2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3

  2012cites this paper
• Implications of rapid virological response in hepatitis C therapy in the US veteran population

  2012cites this paper
• Vitamin D Levels and Il28B Polymorphisms are Related to Rapid Virological Response to Standard of Care in Genotype 1 Chronic Hepatitis C

  2012cites this paper
• Treatment of chronic hepatitis C

  2012cites this paper
• Response‐guided and ‐unguided treatment of chronic hepatitis C

  2012cites this paper
• Response-Guided Therapy

  2012cites this paper
• Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations

  2012cites this paper
• Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.

  2012cites this paper
• Treatment extension may benefit female genotype 1 chronic hepatitis C patients with complete early virological response to peginterferon‐alpha‐2b and ribavirin combination therapy

  2012cites this paper
• Response guided therapy in patients with chronic hepatitis C - yesterday, today and tomorrow.

  2012cites this paper
• Treatment with Interferon and Ribavirin

  2012cites this paper
• Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response.

  2012cites this paper
• A multicenter study to clarify the optimal HCV-RNA negative period during combined therapy with pegylated interferon plus ribavirin in patients with chronic hepatitis caused by HCV genotype 2.

  2012cites this paper